The FDA approved the use of Johnson & Johnson's Sirturo, or bedaquiline, in combination with other drugs, to treat patients with multidrug-resistant tuberculosis. Sirturo, developed by Janssen Therapeutics, is the first tuberculosis drug to gain approval in 40 years. Because of the possibility of fatal heart problems, Sirturo will carry a boxed warning.

Full Story:
Reuters, MSN

Related Summaries